Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
Rigel Pharmaceuticals presented data on GAVRETO (pralsetinib) at ESMO Congress 2026. Pooled trial analysis showed a 53% overall response rate in RET fusion-positive solid tumors. Additional data highlighted first-line outcomes and quality of life in RET fusion-positive NSCLC and thyroid cancer. The company aims to expand pralsetinib's use in RET fusion-positive cancers.
How this was made
The 30-second read
Why it matters
The disclosed ORR and durability data expand the drug's potential indication set, likely prompting analyst upgrades and short‑covering activity.
Market read
First disclosure of multi‑cohort efficacy data; expected to move RIGL stock and influence peer biotech valuations.
What to watch
Regulatory review timelines and reimbursement landscape could temper price gains.
Background
Rigel is a commercial‑stage biotech focused on RET‑fusion cancers; GAVRETO is already approved for RET‑positive NSCLC and thyroid cancer.
Ticker impact
Rigel Pharmaceuticals announced pooled clinical data for GAVRETO (pralsetinib) showing a 53% overall response rate across RET fusion‑positive solid tumors, with high ORRs in thyroid and NSCLC cohorts.
upward pressure as market prices in the robust response rates and potential expansion of the drug's label.
First‑time disclosure of multi‑cohort ORR results, including 81% in thyroid cancer and 75% in first‑line NSCLC, represents material clinical progress for a commercial‑stage biotech.
Market effects
Positive data may lift other RET‑targeted or rare‑cancer biotech stocks.
US biotech sector could see modest gains as investors re‑price pipeline expectations.
Limited to biotech investors; no broad market effect.
Counterpoint
Skeptics may question durability of responses and safety signals, potentially limiting upside.
Key entities
- companyRigel Pharmaceuticals
US‑listed biotech (Nasdaq: RIGL) developing pralsetinib.
- drugGAVRETO (pralsetinib)
Selective RET inhibitor approved for RET‑fusion NSCLC and thyroid cancer.
